EP Patent

EP4114464A4 — METHOD OF TREATING CANCER WITH A COMBINATION OF A PD-1 ANTAGONIST, A CTLA4 ANTAGONIST AND LENVATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF

Assigned to Eisai R&D Management Co Ltd · Expires 2024-05-01 · 2y expired

What this patent protects

Patent listed against lenvatinib-mesylate.

Drugs covered by this patent

Patent Metadata

Patent number
EP4114464A4
Jurisdiction
EP
Classification
—
Expires
2024-05-01
Drug substance claim
No
Drug product claim
No
Assignee
Eisai R&D Management Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.